Stable pharmaceutical composition containing 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9867829
APP PUB NO 20150224102A1
SERIAL NO

14417992

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a stable pharmaceutical composition comprising amorphous or crystalline linagliptin or a pharmaceutically acceptable salt of linagliptin, mannitol, copovidone, and magnesium stearate, processes for preparing the stable pharmaceutical composition, and a container comprising the stable pharmaceutical composition.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
SANDOZ AG4051 BASEL

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Anker, Georg Kundl, AT 4 1
Bacher, Johann Kundl, AT 1 0
Hotter, Andreas Kundl, AT 25 116
Schwarz, Franz X Kundl, AT 5 2

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 16, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 16, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00